retatrutide and glucagon vs Tirzepatide: Key Differences Explained (2026) The TRIUMPH-1 Phase 3 results

More recently, tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, has demonstrated superior weight-reducing effects compared with both placebo and semaglutide, particularly in the SURMOUNT trials, with these benefits sustained for up to 72 weeks [79,80,81]

Gastrointestinal side effects (nausea, vomiting, diarrhoea) affecting 2040% of patients may trigger autonomic sweating responses as a physiological stress reaction

An attorney can ensure that all legal requirements are met and that the case is filed in the appropriate courthouse

Semaglutide is also prescribed for long-term weight management in individuals who are obese (with a body mass index of 30 or higher) or overweight (with a body mass index of 27 or higher) with at least one weight-related condition such as cardiovascular disease, high blood pressure, or type 2 diabetes